|
English
|
正體中文
|
简体中文
|
0
|
|
???header.visitor??? :
50945784
???header.onlineuser??? :
1082
???header.sponsordeclaration???
|
|
|
|
???tair.name??? >
???browser.page.title.author???
|
"andrew d"???jsp.browse.items-by-author.description???
Showing items 1-4 of 4 (1 Page(s) Totally)
1
View [10|25|50] records per page
| 國立成功大學 |
2024-06 |
Independent data collectors decrease bias in the measurement of adherence to anterior cruciate ligament injury prevention programs
|
Hsu;Janet;Ling;Daphne, I.;Schneider;Brandon, L.;Boyle;Caroline;Janosky;Joseph;Pearle;Andrew, D.;Kinderknecht;James;Marx;Robert, G. |
| 國立成功大學 |
2019-08-6 |
Functional Relevance of Interleukin-1 Receptor Inter-domain Flexibility for Cytokine Binding and Signaling
|
Ge;Jiwan;Remesh;Soumya, G.;Hammel;Michal;Pan;Si;Mahan;Andrew, D.;Wang;Shuying;Wang;Xinquan |
| 國家衛生研究院 |
2017-06-26 |
Subgroup analysis by prior non-liposomal irinotecan therapy in NAPOLI-1: A phase 3 study of nal-IRI +/- 5-fluorouracil/leucovorin in patients with metastatic pancreatic ductal adenocarcinoma previously treated with gemcitabine-based therapy
|
Jean-Frederic, B;Richard, H;Li, CP;Andrea, WG;Gyorgy, B;Andrew, D;Shan, YS;Gayle, J;Teresa, M;Lee, H;David, C;Chiu, CF;Gilberto, S;Fadi, B;Daniel, V;Chen, LT;Khalid, M;Parul, B;Floris, D;Jens, S |
| 國家衛生研究院 |
2016-06 |
Nanoliposomal irinotecan (nal-IRI)-containing regimens versus nab-paclitaxel plus gemcitabine as first-line therapy in patients with metastatic pancreatic adenocarcinoma (mPAC): A randomized, open-label phase 2 study
|
Andrew, D;Ramesh, R;Brooke, B;Bruce, B;Deyaa, A;Eliel, B;Chen, LT |
Showing items 1-4 of 4 (1 Page(s) Totally)
1
View [10|25|50] records per page
|
